Matthew Lalli is a post-doc in the Milbrandt and Mitra labs interested in understanding neurological diseases using patient derived stem cells. He is trying to apply new technologies to improve disease-in-a-dish modeling by expanding the number of relevant cell types we can generate. Through Cas9-based transcriptional modulation of disease-causing genes, he hopes to discover molecular underpinnings of disease phenotypes. Altogether, these projects have the potential to identify novel targets for treating neurological diseases such as Alzheimer’s and autism.
Postdoctoral Research Scholar